2022-09-16T04:55:27+03:00[Europe/Moscow] en true <p>Kanuma (sebelipase alfa)</p>, <p>LAL-D</p>, <p>-ase</p>, <p>-mab</p>, <p>CRYSVITA (burosumab-twza)</p>, <p>Mipomersen</p>, <p>Macugen (pegaptanib sodium injection)</p>, <p>-rsen</p>, <p>-apt</p>, <p>aptamers</p>, <p>Patisran</p>, <p>siRNA</p>, <p>MELAS</p>, <p>antioxidants &amp; vitamins</p>, <p>-tecans</p>, <p>(CAMPTOSAR) Ironotecan</p>, <p>(ADRIAMYCIN) Doxorubicin</p>, <p>damages cardiomyocytes by inhibiting Topoisomerase 2B</p>, <p>550 mg/m2</p>, <p>-floxacin</p>, <p>Fluoroquinolone</p>, <p>Histones</p>, <p>Histone acetyltransferase (HAT) </p>, <p>Histone deacetylase</p>, <p>True</p>, <p>HDAC inhibitors</p>, <p>-inostats</p>, <p>Zn+2 </p>, <p>DNA ligase</p>, <p>200 nucleotides</p>, <p>10 nucleotides</p>, <p>valacyclovir &amp; acyclovir</p>, <p>II, III, IV</p>, <p>Ivacaftor </p>, <p>Missense </p>, <p>Nonsense mutation</p>, <p>nonsense; cannot transport cl ions out of cell</p>, <p>2 copies of F508del mutation; frameshift (in frame)</p>, <p>Lumacaftor</p>, <p>ivacaftor &amp; lumacaftor </p>, <p>Trikafta </p>, <p>Exondys 51 (eteplirsen)</p>, <p>out of frame; in frame</p>, <p>SPINRAZA (nusinersen)</p>, <p>episomes</p>, <p>Zolgensma</p>, <p>PARP</p>, <p>double-strand breaks </p>, <p>PARP inhibitors</p>, <p>BRCA</p>, <p>HR DNA repair pathways</p>, <p>-paribs</p> flashcards
Medications & MOA for Exam 1 (genomics)

Medications & MOA for Exam 1 (genomics)

  • Kanuma (sebelipase alfa)

    -is an innovative enzyme therapy approved for treatment of patients with lysosomal acid lipase deficiency (LAL-D).

    -

  • LAL-D

    -decreased or loss-of-function of the LAL enzyme

    -leads to continuous accumulation of cholesteryl esters and triglycerides in the liver, blood vessel walls and other tissue

    -can result in progressive complications in multiple organs; liver, spleen, and intestine

  • -ase

    What end suffix refers to enzyme based medications?

  • -mab

    What end suffix refers to monoclonal antibody therapy?

  • CRYSVITA (burosumab-twza)

    first and only FDA- approved treatment for X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.

  • Mipomersen

    targets human mRNA for apo B-100, the prinicpal lipoprotein of LDL. The binding of this drug to mRNA results in degradation of the mRNA thus inhibiting translation of the apo B-100 protein.

  • Macugen (pegaptanib sodium injection)

    anti-VEGF inhibitor approved by the FDA for the treatment of Wet Age-Related Macular Degeneration. (injected into the eye)

  • -rsen

    AS-ON nucleotides are denoted by what suffix?

  • -apt

    Aptamers are denoted by what in their name?

  • aptamers

    are RNA or DNA nucleic acid drugs that recognize specific proteins. They fold up into unique 3-D structures, allowing them to bind specifically to proteins.

  • Patisran

    doubled-stranded siRNA that causes degradation of mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

  • siRNA

    -therapeutics used to target host mRNA

    -"kill the messenger"

    -NOT CRISPR technology

  • MELAS

    rare progressive neurodegenerative disease caused by the decreased ability of cells to produce sufficient energy in the form of ATP

  • antioxidants & vitamins

    What drugs are most often used to treat MELAS

  • -tecans

    topoisomerase inhibitors include what in their name?

  • (CAMPTOSAR) Ironotecan

    -topoisomerase I inhibitor

    -anticancer agent

  • (ADRIAMYCIN) Doxorubicin

    -cause apoptosis of cancer cells by:

    -intercalation into DNA

    -Topisomerase IIa inhibition

  • damages cardiomyocytes by inhibiting Topoisomerase 2B

    What adverse effects does Doxorubicin have?

  • 550 mg/m2

    What is the lifetime dose of Doxorubicin?

  • -floxacin

    How do we identify fluoroquinolone antibiotics?

  • Fluoroquinolone

    inhibits bacterial DNA gyrase and bacterial topoisomerase IV.

  • Histones

    these proteins work to "pack" DNA to protect, but also permit access to the information in the DNA for replication & transcription.

  • Histone acetyltransferase (HAT)

    increases gene activity by creating a more open chromatin

  • Histone deacetylase

    -removes acetyl groups

    -leads to gene repression through condensation of chromatin

    -"on-off switch"

  • True

    HDAC inhibitors render chromatin "transcriptionally competent" by keeping chromatin in open state. T/F?

  • HDAC inhibitors

    -block erasing of acetyl groups

    -causes accumulation of acetylated histones

    -induces apoptosis of cancer cells

  • -inostats

    Which stem denotes HDAC inhibitors?

  • Zn+2

    What is one basic structure requirement of all HDAC inhibitors?

  • DNA ligase

    completed fragments that are joined together by this enzyme, catalyses the formation of a phosphodiester bond between the 3; -OH end of one fragment and the 5'-P end of the next.

  • 200 nucleotides

    How far apart are RNA primers?

  • 10 nucleotides

    How long are RNA primers?

  • valacyclovir & acyclovir

    DNA polymerase inhibitors that are used to treat Herpes Simplex Virus (HSV)?

  • II, III, IV

    Which CFTR mutation classes do we have approved therapeutics for?

  • Ivacaftor

    -CFTR gate potentiator

    - first-in-class treatment of CF

    -responsive to G551D

  • Missense

    Ivacaftor is used for what type of mutations?

  • Nonsense mutation

    -change in genetic code that results in coding for a stop codon; protein is generally LOF or function is impeded.

  • nonsense; cannot transport cl ions out of cell

    Class 1 CFTR mutations result from what kind of mutations; and how does this affect the protein?

  • 2 copies of F508del mutation; frameshift (in frame)

    Orkambi is indicated for patients with what type of gene? What mutation class does this fall under?

  • Lumacaftor

    -acts as a small molecule chaperone for CTF and helps it get to cell surface-referred to as correctors.

  • ivacaftor & lumacaftor

    Orkambi is a combination therapy utilizing what medications?

  • Trikafta

    -first triple combination therapy approved for patients 6 years and older who have at least one F508del mutation in the CFTR gene

  • Exondys 51 (eteplirsen)

    -injection

    -antisense oligonucleotide

    -for patients who have confirmed mutation of DMD gene

  • out of frame; in frame

    EXONDYS-51 converts _____ to ______

  • SPINRAZA (nusinersen)

    -SM2 AS-ON

    -administered by intrathecal injection (spinal)

    -binds to exon 7 and increases inclusion forming production of full-length SMN protein

  • episomes

    -standalone DNA constructs that do not integrate into the genome.

    -replicate independently of host genome

  • Zolgensma

    -wild-type copy of SMN-dsDNA gene packaged in adeno-associated virus 9 vector

    -delivered IV

    -delivered to non-dividing cells such as

  • PARP

    -nuclear enzyme that facilitates the repair of DNA single-strand breaks (SSBs) through a process called Base Excision Repair (BER)

  • double-strand breaks

    When PARP's are inhibited, unrepaired SSBs colliding with replication forks give rise to lethal ____

  • PARP inhibitors

    -function in a process termed synthetic lethality

    -this drug is used in tumor cells that already have defects in DSB repair pathways

  • BRCA

    -tumor suppressor gene/protein

  • HR DNA repair pathways

    It is known that BRCA1/2 mutation genotypes have defective ___

  • -paribs

    PARP inhibitors are denoted by what suffix?